Carlos Lopez-Espina

Bio:

Carlos G. Lopez-Espina leads all research and development at Prenosis, a biology-based technology company that profiles patient biology to unlock novel treatments for the most serious hospital conditions. At Prenosis, he has built the world's most comprehensive platform for understanding acute immune response — the Immunix™ platform — which powers a suite of AI-based diagnostics grounded in each patient's unique biological profile.

Most notably, he led the development of Sepsis ImmunoScore™, the first FDA-cleared AI diagnostic tool for sepsis, recognized by Time Magazine as one of the Best Inventions of 2024. As a next step in Prenosis' vision of profiling biology to enable novel treatments, he is advancing a new AI-biomarker that identifies patients most likely to benefit from corticosteroid therapy in severe respiratory infection — moving beyond diagnosis toward individualized treatment decisions for the most serious conditions in acute care.

Before joining Prenosis, Lopez-Espina held R&D and product development roles across both startups and established medical device companies, where he led multiple successful FDA clearances and commercial launches — including a best-in-class point-of-care device for global hemostasis.

An engineer by training, he studied aeronautical engineering at the Polytechnic University of Madrid and earned his M.S. in Mechanical Engineering from the University of Illinois at Chicago — a background that informs his systems-level approach to solving biology's hardest problems.